NorDiag ASA Reports Earnings Results for the Year Ended December 31, 2011
April 27, 2012 at 02:04 pm EDT
Share
NorDiag ASA reported earnings results for the year ended December 31, 2011. For the year, the company reported total operating revenues of NOK 30,406,000, operating loss of NOK 65,999,000, loss before taxes of NOK 125,973,000, net loss from continuing operations of NOK 125,973,000, net loss of NOK 125,973,000 or NOK 1.64 per diluted share compared to the total operating revenues of NOK 21,199,000, operating loss of NOK 32,907,000, loss before taxes of NOK 59,436,000, net loss from continuing operations of NOK 59,436,000, net loss of NOK 59,436,000 or NOK 0.95 per diluted share for the previous year. Net cash used in operating activities was NOK 20,374,000 compared to the NOK 17,796,000 for the previous year. Investment in intangible assets was NOK 4,034,000 compared to the NOK 2,267,000 for the previous year. Investment in non-current assets was NOK 5,856,000 compared to the NOK 3,095,000 for the previous year.
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Companyâs products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
NORDA ASA 